What is Nuclidium?
Nuclidium operates at the intersection of advanced chemistry and clinical oncology, focusing on the development of copper-based radiopharmaceuticals. By utilizing Copper-61 for precise diagnostics and Copper-67 for targeted therapeutics, the company is addressing the inherent limitations of current radiotheranostic modalities. Its platform is designed to provide superior clinical outcomes, particularly in the fields of oncology and women's health. With a robust operational footprint in Europe, Nuclidium integrates deep clinical expertise with scalable manufacturing to deliver high-impact medical solutions. The company's market position is defined by its commitment to overcoming the technical hurdles of isotope-based medicine, positioning it as a leader in the evolving landscape of precision medicine.
How much funding has Nuclidium raised?
Nuclidium has raised a total of $101.4M across 2 funding rounds:
Series A
$2.9M
Series B
$98.5M
Series A (2021): $2.9M, investors not publicly disclosed
Series B (2025): $98.5M led by Kurma Partners, Angelini Ventures, Wellington Partners, and Neva Sgr
Key Investors in Nuclidium
Kurma Partners
A prominent European venture firm specializing in healthcare innovation, supporting companies from pre-seed to growth stages with a focus on drug development.
Angelini Ventures
A global venture capital firm dedicated to transforming healthcare through technology and addressing unmet needs in vulnerable populations.
Wellington Partners
A leading European venture capital firm that invests in early- and growth-stage life science companies, including therapeutics and diagnostics.
What's next for Nuclidium?
With the successful closure of this major strategic investment, Nuclidium is set to enter a critical phase of clinical expansion. The capital will likely be deployed to advance its lead candidates through rigorous clinical trials and to optimize its supply chain for copper-based isotopes. As the company scales, the focus will shift toward establishing broader clinical partnerships and navigating the regulatory pathways required for global market entry. Investors are closely watching how Nuclidium leverages this liquidity to solidify its competitive advantage in the radiotheranostics sector, potentially setting a new benchmark for efficacy and accessibility in cancer treatment.
See full Nuclidium company page
